| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 2-Yr Return |
|---|---|---|---|---|---|
|
PGEN
Precigen
|
Sep 26, 2025 | BUY |
Buy
+404.8% avg upside
11 analysts
|
— | +34.8% |
|
BLTE
Belite Bio, Inc. ADR
|
May 15, 2025 | BUY |
Strong Buy
+25.0% avg upside
10 analysts
|
— | +106.0% |
|
INSM
Insmed
|
Apr 11, 2025 | BUY |
Strong Buy
+82.1% avg upside
36 analysts
|
— | +43.6% |
|
EYPT
EyePoint Pharmaceuticals
|
Feb 05, 2025 | BUY |
Strong Buy
+124.1% avg upside
17 analysts
|
— | +68.6% |
|
FBIO
Fortress Biotech
|
Aug 14, 2023 | BUY |
Strong Buy
+163.3% avg upside
12 analysts
|
$5.00
67.20% Upside
|
-75.8% |
|
LPCN
Lipocine
|
Jul 27, 2023 | BUY |
Strong Buy
+672.5% avg upside
4 analysts
|
$33.00
1316.35% Upside
|
-32.6% |
|
AYTU
Aytu BioScience
|
Jun 09, 2023 | HOLD |
Strong Buy
+700.8% avg upside
7 analysts
|
— | +31.9% |
|
PRQR
ProQR
|
May 17, 2023 | BUY |
Strong Buy
+516.3% avg upside
18 analysts
|
$4.50
138.03% Upside
|
-7.4% |
|
NOVN
Novan
|
Dec 02, 2022 | BUY |
Buy
6 analysts
|
$8.00
|
· |
|
OCGN
Ocugen
|
Jun 02, 2022 | BUY |
Strong Buy
+646.0% avg upside
17 analysts
|
$4.50
262.96% Upside
|
-29.1% |
|
CALC
CalciMedica
|
May 11, 2022 | BUY |
Buy
+3672.8% avg upside
9 analysts
|
$35.00
4533.36% Upside
|
-4.1% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.